Skip to main content
. 2010 Oct 5;19(2):266–273. doi: 10.1038/mt.2010.211

Figure 1.

Figure 1

FREG inhibits PDGF- induced cell proliferation. (a) FCS-induced RASMC proliferation (48 hours) was examined in the presence or in the absence of increasing doses of FREG or the negative control scrambled peptide (SCR). FREG reduced cell proliferation in a dose-dependent way reaching the plateau at 10 ng/ml, while the SCR was ineffective at all tested doses (*P < 0.05 versus FCS). (b) FREG reduced in a dose-dependent way PDGF-BB (10 ng/ml)-induced cell proliferation, reaching the plateau at 10 ng/ml. The SCR was ineffective at all tested doses (*P < 0.05 versus PDGF-BB). (c) FREG (10 ng/ml) reduced PDGF-BB mitogenic activity on RASMC in a time-dependent way, while SCR (10 ng/ml) was ineffective (*P < 0.05 versus PDGF-BB). Data are expressed as mean ± SD of three experiments. ctrl, control; PDGF, platelet-derived growth factor.